Since joining Kirkland & Ellis, Jenny has been involved in the following:
- Magnum Opus Acquisition Limited (NYSE: OPA), a publicly traded special purpose acquisition company, on its proposed business combination with Forbes Global Media Holdings Inc., the iconic business information brand, and subsequent US$200 million strategic investment from Binance, one of the world’s largest cryptocurrency and blockchain infrastructure providers
- The joint sponsors and underwriters on the global offering and listing of CANbridge Pharmaceuticals Inc. (HKSE: 1228), a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of biotech therapies, on The Stock Exchange of Hong Kong Limited on December 10, 2021
- Beijing Airdoc Technology Co., Ltd. (HKSE: 2251), a global leader and pioneer in providing AI-empowered retina-based early detection, auxiliary diagnosis and health risk assessment solutions, on its US$215 million global offering and listing on The Stock Exchange of Hong Kong Limited
- Suzhou Basecare Medical Corporate Limited (HKSE: 2170), an innovative platform of genetic testing solutions for assisted reproduction in China, in its US$233 million global offering of H-shares and listing on the Hong Kong Exchanges and Clearing Limited
Prior to joining Kirkland & Ellis, Jenny has been involved in the following:
- Joy Spreader Interactive Technology. Ltd (HKSE: 6988) in connection with its IPO on the Main Board of HKEx. The offering raised net proceeds of HK$1.56 billion (approximately US$200 million). Joy Spreader is one of the leading performance-based we-media marketing service providers in China
- Yum China Holdings, Inc. (HKSE: 9987, NYSE: YUMC) in its HK$17 billion (US$2.2 billion) secondary listing on the Main Board of HKEx. Yum China is the largest restaurant company in China with flagship brands including KFC and Pizza Hut, as well as emerging brands such as Little Sheep, Huang Ji Huang, COFFii & JOY, East Dawning, Taco Bell, and Lavazz
- Ocumension Therapeutics (HKSE: 1477), in its HK$1.4 billion (approximately US$182.5 million) IPO on the Main Board of HKEx. Ocumension Therapeutics, which started its business in 2017, is an ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first or best-in-class ophthalmic therapies
- Kangji Medical Holdings Limited (HKSE: 9997) on its HK$3.1 billion (approximately US$404 million) IPO on the Main Board of HKEx as Hong Kong and U.S. legal counsel. Goldman Sachs (Asia) LLC, CLSA Capital Markets Limited and Merrill Lynch Far East Limited acted as joint sponsors for the transaction
- Rizhao Port Jurong Co., Ltd., in its global offering and listing of H-Shares on the Main Board of the Hong Kong Stock Exchange. Rizhao Port Jurong Co., Ltd. is the largest port for grain and woodchip imports in China and a subsidiary of Rizhao Port Co., Ltd. (600017.SH). Proceeds: US$69.65 million
- CanSino Biologics Inc., in its global offering and listing of H-Shares on the Main Board of the Hong Kong Stock Exchange. CanSino Biologics Inc. is a bio-tech leader in research and development, manufacturing and commercialization of vaccine products for human use in China. Proceeds: US$160.5 million
- BabyTree Group in its global offering on the Main Board of the Hong Kong Stock Exchange. BabyTree Group is one of the largest and most active M&C-focused community-based platforms in China. Proceeds: US$218 million
- Shandong Gold Mining Co., Ltd., A-shares listed company, in its global offering and listing of H-Shares on the Main Board of the Hong Kong Stock Exchange. Shandong Gold is engaged in the mining and smelting of gold. Proceeds: US$594 million
- Xinte Energy Co., Ltd., in its global offering and listing of H-Shares on the Main Board of the Hong Kong Stock Exchange. Proceeds: US$166 million
- CITIC CCI Securities Co., Ltd. in its global offering and listing of H-Shares on the Main Board of the Hong Kong Stock Exchange. Proceeds: US$1.135 billion
